Daiwa Securities Group Inc. - RECURSION PHARMACEUTICALS IN ownership

RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 129 filers reported holding RECURSION PHARMACEUTICALS IN in Q1 2022. The put-call ratio across all filers is 1.41 and the average weighting 1.8%.

Quarter-by-quarter ownership
Daiwa Securities Group Inc. ownership history of RECURSION PHARMACEUTICALS IN
ValueSharesWeighting
Q2 2024$59
-46.4%
7,868
-29.0%
0.00%
-100.0%
Q1 2024$110
-5.2%
11,082
-5.8%
0.00%0.0%
Q4 2023$116
+1833.3%
11,759
+1508.6%
0.00%
Q3 2023$6
+20.0%
7310.0%0.00%
Q2 2023$5
-91.1%
731
-91.3%
0.00%
Q1 2023$56
+5.7%
8,411
+21.8%
0.00%
Q4 2022$53
-99.2%
6,903
+1029.8%
0.00%
Q3 2022$7,000
-92.9%
611
-95.0%
0.00%
-100.0%
Q2 2022$99,000
+90.4%
12,195
+68.4%
0.00%
Q1 2022$52,000
-40.9%
7,241
+41.6%
0.00%
-100.0%
Q4 2021$88,0005,1140.00%
Other shareholders
RECURSION PHARMACEUTICALS IN shareholders Q1 2022
NameSharesValueWeighting ↓
Two Sigma Ventures, LP 903,400$9,612,000100.00%
Obvious Management Services, L.L.C. 3,985,087$42,401,000100.00%
DCVC Opportunity Fund II GP, LLC 3,951,141$42,040,00054.37%
Data Collective IV GP, LLC 5,941,120$63,214,00049.97%
MIC Capital Management UK LLP 8,451,758$89,927,00016.21%
MV Management XI, L.L.C. 1,971,908$20,981,00015.20%
ArchPoint Investors 1,116,126$11,876,0004.85%
HARVARD MANAGEMENT CO INC 1,509,254$16,058,0002.00%
PLATINUM INVESTMENT MANAGEMENT LTD 2,251,971$23,961,0001.00%
Duquesne Family Office 1,385,950$14,747,0000.84%
View complete list of RECURSION PHARMACEUTICALS IN shareholders